Literature DB >> 26529357

Saving in medical costs by achieving guideline-based asthma symptom control: a population-based study.

M Sadatsafavi1,2, W Chen3, H Tavakoli1, J D Rolf4, R Rousseau1, J M FitzGerald1,2.   

Abstract

BACKGROUND: Asthma control is increasingly used as an outcome measure in asthma trials. Economic evaluations of asthma interventions require converting the impact of interventions on control to impact on resource use. The purpose of this study was to estimate the savings in direct costs by achieving asthma symptom control as defined in the Global Initiative for Asthma (GINA) 2014 management strategy.
METHODS: Adolescents and adults with asthma were recruited through random digit dialing. Asthma control per GINA and the use of healthcare resources were assessed at baseline and three-monthly visits up to 1 year. We used regression models to associate costs, measured in 2012 Canadian dollars ($), with symptom control, adjusting for potential confounding variables.
RESULTS: The final sample included 517 individuals (average age 48.9, 65.8% female) with mostly mild-moderate asthma contributing 2033 follow-up visits. In 598 (29.4%), 809 (39.8%), and 626 (30.8%) of visits, asthma was symptomatically controlled, partially controlled, or uncontrolled, respectively. The average 3-month costs of asthma were $134.5. Of these, 20.5% were attributable to inpatient care, 47.8% to outpatient care, and 31.5% to medication. Compared to controlled asthma, partially controlled asthma was associated with a nonsignificant increase of $9.5 (95% CI -$13.6 - $32.6) in adjusted 3-month costs and uncontrolled asthma with a statistically significant increase of $81.7 (95% CI $48.5 - $114.9).
CONCLUSION: A substantial fraction of this population-based sample of largely mild-moderate asthmatics was symptomatically uncontrolled. Achieving symptom control was associated with a reduction in direct costs. The adjusted values from this study can be used to inform cost-effectiveness analyses of asthma treatments.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; cost-effectiveness; costs; outcomes

Mesh:

Year:  2015        PMID: 26529357     DOI: 10.1111/all.12803

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

1.  Randomized Controlled Trial of Health Coaching for Vulnerable Patients with Chronic Obstructive Pulmonary Disease.

Authors:  David H Thom; Rachel Willard-Grace; Stephanie Tsao; Danielle Hessler; Beatrice Huang; Denise DeVore; Chris Chirinos; Jessica Wolf; DorAnne Donesky; Chris Garvey; George Su
Journal:  Ann Am Thorac Soc       Date:  2018-10

2.  Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US.

Authors:  Zafar Zafari; Mohsen Sadatsafavi; J Mark FitzGerald
Journal:  Cost Eff Resour Alloc       Date:  2018-01-30

3.  The Electronic Asthma Management System (eAMS) improves primary care asthma management.

Authors:  Samir Gupta; Courtney Price; Gina Agarwal; David Chan; Sanjeev Goel; Louis-Philippe Boulet; Alan G Kaplan; Gerald Lebovic; Muhammad Mamdani; Sharon E Straus
Journal:  Eur Respir J       Date:  2019-04-25       Impact factor: 16.671

Review 4.  The Global Impact of Asthma in Adult Populations.

Authors:  Oladunni Enilari; Sumita Sinha
Journal:  Ann Glob Health       Date:  2019-01-22       Impact factor: 2.462

5.  Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada.

Authors:  Bryan Ng; Mohsen Sadatsafavi; Abdollah Safari; J Mark FitzGerald; Kate M Johnson
Journal:  BMJ Open       Date:  2019-11-07       Impact factor: 2.692

6.  Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.

Authors:  Mondher Mtibaa; Subhajit Gupta; Madhusubramanian Muthukumar; Jessica Marvel; Harneet Kaur; Ryotaro Ishikawa; Ron Olivenstein
Journal:  Clinicoecon Outcomes Res       Date:  2021-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.